Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Akero Therapeutics, Inc. (AKRO)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | 0.0 | 0.0 | 18.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 25.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | -7.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | -38.8% | | | | | |
| Selling, general and administrative [+] | 7.6 | 7.0 | 7.1 | 6.2 | 5.5 | 4.7 | 4.9 | 5.0 |
| General and administrative | 7.6 | 7.0 | 7.1 | 6.2 | 5.5 | 4.7 | 4.9 | 5.0 |
| Research and development | 28.0 | 21.8 | | 21.4 | 20.5 | 27.7 | 19.5 | 24.0 |
| Other operating expenses | | | 11.2 | | | | | |
| EBITDA [+] | -35.6 | -28.7 | | -27.6 | -26.0 | -32.4 | -24.3 | -29.0 |
| EBITDA growth | 29.1% | 10.4% | -21.6% | -4.7% | 72.3% | 8.9% | 13.1% | 76.0% |
| EBITDA margin | | | -138.8% | | | | | |
| Depreciation and amortization | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -35.6 | -28.8 | -25.4 | -27.6 | -26.1 | -32.4 | -24.4 | -29.0 |
| EBIT growth | 29.1% | 10.4% | -21.6% | -4.7% | 72.2% | 8.9% | 13.1% | 76.0% |
| EBIT margin | | | -138.8% | | | | | |
| Interest expense | 0.9 | 0.5 | 0.4 | 0.1 | | | | |
| Interest expense | 0.9 | 0.5 | 0.4 | 0.1 | | | | |
| Other income (expense), net [+] | 5.4 | 3.4 | 2.7 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other non-operating income | 5.4 | 3.4 | | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other | -5.4 | -3.4 | -2.7 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -31.1 | -25.8 | -23.1 | -27.4 | -26.0 | -32.4 | -24.3 | -28.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -31.1 | -25.8 | -23.1 | -27.4 | -26.0 | -32.4 | -24.3 | -28.9 |
| Net margin | | | -125.9% | | | | | |
| |
| Basic EPS [+] | ($0.60) | ($0.55) | ($0.49) | ($0.77) | ($0.74) | ($0.93) | ($0.70) | ($0.83) |
| Growth | -22.6% | -26.0% | -47.0% | -6.8% | 71.2% | -1.4% | 10.9% | 46.7% |
| Diluted EPS [+] | ($0.60) | ($0.55) | ($0.49) | ($0.77) | ($0.74) | ($0.93) | ($0.70) | ($0.83) |
| Growth | -22.6% | -26.0% | -47.0% | -6.8% | 71.2% | -1.4% | 10.9% | 46.7% |
| |
| |
| Shares outstanding (basic) [+] | 51.9 | 46.9 | 46.8 | 35.4 | 35.0 | 34.8 | 34.9 | 34.8 |
| Growth | 46.6% | 34.1% | 34.3% | 1.6% | 0.8% | 10.7% | 2.5% | 21.7% |
| Shares outstanding (diluted) [+] | 51.9 | 46.9 | 46.8 | 35.4 | 35.0 | 34.8 | 34.9 | 34.8 |
| Growth | 46.6% | 34.1% | 34.3% | 1.6% | 0.8% | 10.7% | 2.5% | 21.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|